CMS Seeking Comment on CLIA Rule Allowing Remote Access to Digital Laboratory Data
The Centers for Medicare & Medicaid Services is seeking comment on a proposed rule to amend regulations from the Clinical Laboratory Improvement...
1 min read
On May 29, Medicare announced it would expand coverage for genomic sequence analysis panels in the treatment of hematolymphoid diseases.
The local coverage determination (LCD) “provides limited coverage for genomic sequence analysis panels under specific clinical circumstances.” Specifically, these multi-gene panel tests would be used for diagnosis, risk stratification, and treatment planning for patients with hematolymphoid diseases, including newly diagnosed or relapsed/refractory acute myelogenous leukemia, myelodysplastic syndromes with nondiagnostic assessments, and myeloproliferative neoplasms requiring risk stratification or disease monitoring.
The College of American Pathologists applauded the proposed updates in a 2024 letter, expressing support for the decision to broaden coverage. According to CAP, the policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.
The revision is effective for services performed on or after July 13, 2025.
Sources:
https://www.cap.org/advocacy/latest-news-and-practice-data/june-10-2025#story5
Bill to Reform No Surprises Act Arbitration Process Introduced in House
Rep. Frank Pallone (D-N.J.), ranking member of the House Energy & Commerce Committee, introduced legislation to fix the No Surprises Act arbitration...
UHC Drops Lp(a) from Its Non-Coverage List
UnitedHealthcare has released an updated version of its Cardiovascular Disease Risk Tests medical policy for Commercial and Individual Exchange...